Fostamatinib is an oral spleen tyrosine kinase (SYK) inhibitor that has been approved for the treatment of chronic immune thrombocytopenia (ITP) in adults who have not responded sufficiently to previous treatment. It inhibits the activity of spleen tyrosine kinase (SYK), reduces the attack and destruction of platelets by immune cells, increases the number and function of platelets, and relieves patients' bleeding symptoms.

Precautions for Fostamatinib

When patients are treated with Fostamatinib, please pay close attention to their own medication reactions and keep in close contact with their doctors.

Diarrhea

When patients experience diarrhea symptoms during Fostamatinib treatment, supportive care measures can be taken in the early stage. If diarrhea symptoms continue to worsen and reach grade 3 or above, the doctor may consider suspending, reducing or stopping the medication. Throughout the treatment process, the doctor will pay close attention to the patient's diarrhea symptoms and take appropriate treatment measures according to the specific situation.

Hypertension

Fostamatinib can affect certain signaling pathways in the body related to blood pressure regulation. For patients who already have hypertension, Fostamatinib may further increase blood pressure and increase the risk of cardiovascular diseases such as myocardial infarction and stroke. Before the dose of Fostamatinib stabilizes, blood pressure should be monitored every 2 weeks, and appropriate treatment measures should be taken according to the patient's specific situation.

Other precautions

When using Fostamatinib for treatment, patients also need to pay attention to liver toxicity, neutropenia, and embryo-fetal toxicity.

The use of Fostamatinib must strictly follow the doctor's instructions, pay attention to possible side effects, and pay special attention to the use restrictions of Fostamatinib in special populations. During use, if the patient has any questions or discomfort, he should consult a doctor in time.

Special population medication of Fostamatinib

The following are some special populations for Fostamatinib:

Pregnant and lactating patients

Fostamatinib may cause damage to the fetus. Before starting treatment, female patients need to undergo pregnancy testing. For female patients who are already pregnant, Dr. Fu will give individualized medication recommendations based on the patient's specific situation. Fostamatinib may be passed to the baby through breast milk, causing adverse effects on the baby's health. Lactating women should avoid breastfeeding during treatment with Fostamatinib and within 1 month after the last dose.

Children and elderly patients

The decline in physiological function of the elderly may lead to slower metabolism and excretion of drugs in the body, increasing the risk of adverse drug reactions. Elderly patients should strictly follow the doctor's medication instructions when using Fostamatinib. The physiological characteristics and drug metabolism ability of children are different from those of adults. It is not recommended for children under 18 years old to use Fostamatinib.

When using Fostamatinib for treatment, patients should strictly follow the doctor's medication recommendations, undergo regular review, and monitor the treatment effect.